Cardiawave
Private Company
Funding information not available
Overview
Cardiawave is a clinical-stage medical device company pioneering a non-invasive, non-implant therapy for calcific aortic stenosis (CAS). Its core technology, Non-Invasive Ultrasound Therapy (NIUT), uses focused ultrasound to soften calcified aortic valves, potentially serving as a standalone treatment for ineligible patients or a preparatory procedure for transcatheter aortic valve replacement (TAVR). The company is backed by significant European and French public grants and a syndicate of private investors, positioning it to address a large and growing unmet need in structural heart disease.
Technology Platform
Non-Invasive Ultrasound Therapy (NIUT) using focused ultrasound to mechanically soften calcific deposits on the aortic valve without surgery or implants.
Opportunities
Risk Factors
Competitive Landscape
Cardiawave's primary competition is the entrenched standard of care: TAVR (Edwards Lifesciences, Medtronic, Boston Scientific) and SAVR. It also competes with other investigational non-implant therapies, such as lithotripsy systems (e.g., Shockwave Medical's intravascular lithotripsy, though used differently) and other devices aiming to modify valve calcium. Its key differentiator is the completely non-invasive, external application of therapy.